Form 8-K - Current report:
SEC Accession No. 0001104659-22-024757
Filing Date
2022-02-17
Accepted
2022-02-17 16:30:54
Documents
12
Period of Report
2022-02-11
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm227003d1_8k.htm   iXBRL 8-K 26299
  Complete submission text file 0001104659-22-024757.txt   197841

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA rigl-20220211.xsd EX-101.SCH 3024
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE rigl-20220211_lab.xml EX-101.LAB 34476
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rigl-20220211_pre.xml EX-101.PRE 22589
6 EXTRACTED XBRL INSTANCE DOCUMENT tm227003d1_8k_htm.xml XML 3506
Mailing Address 1180 VETERANS BOULEVARD SOUTH SAN FRANCISCO CA 94080
Business Address 1180 VETERANS BOULEVARD SOUTH SAN FRANCISCO CA 94080
RIGEL PHARMACEUTICALS INC (Filer) CIK: 0001034842 (see all company filings)

EIN.: 943248524 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-29889 | Film No.: 22648582
SIC: 2834 Pharmaceutical Preparations